BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38154145)

  • 21. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
    Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
    J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
    Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
    Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
    Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of IVF/ICSI outcomes in infertile women with early-stage endometrial cancer and atypical endometrial hyperplasia after conservative treatment.
    Guo Y; Zong X; Li H; Qiao J
    J Assist Reprod Genet; 2022 Jul; 39(7):1643-1651. PubMed ID: 35648323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
    Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
    [No Abstract]   [Full Text] [Related]  

  • 28. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
    He Y; Wang Y; Zhou R; Wang J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
    Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
    BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer].
    Morimoto C; Wang YQ; Zhou R; Wang JL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):936-942. PubMed ID: 36241236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
    Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
    Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
    De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
    Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
    Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
    J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
    Pronin SM; Novikova OV; Andreeva JY; Novikova EG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases.
    Shan Y; Qin M; Yin J; Cai Y; Li Y; Gu Y; Wang W; Wang YX; Chen JY; Jin Y; Pan LY
    Front Oncol; 2021; 11():749881. PubMed ID: 34804936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
    Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
    BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis.
    Adamyan L; Pivazyan L; Isaeva S; Shapovalenko R; Zakaryan A
    Arch Gynecol Obstet; 2024 Jun; 309(6):2289-2305. PubMed ID: 38503850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.